Neuroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin analogs. However, the efficacy of such treatment is low and needs to be optimized. Our study evaluates the potential radiosensitizing effects of inhibition of nicotineamide phosphoribosyltransferase (NAMPT) on 
Introduction
NETs express high levels of somatostatin receptors (SSTR), enabling the use of somatostatin analogs for both imaging and therapeutic purposes. Peptide-receptor radionuclide therapy with radiolabeled somatostatin analogs is used in select cases to treat non-resectable NETs, resulting in symptomatic improvement, enhanced quality of life and prolonged survival. Due to dose-limiting hematotoxicity and nephrotoxicity the cure rate is low (1) , and optimization of this treatment modality is needed. We have previously shown that xenografted intestinal NET cell line GOT1 can be effectively treated with administration of high doses (30 MBq or more) resulted in total tumor eradication, while lower doses (7.5 MBq; "semi-efficient") resulted in 50% tumor reduction followed by progression after 2 weeks (Supplemental Fig. 1 ) (2) . We have also demonstrated a strong antitumor effect of the pyridyl cyanoguanidine GMX1778 (formerly CHS 828) on GOT1 cells both in vitro and in vivo. A weekly oral dose of 250 mg/kg/w completely eradicated the tumors within 3 weeks, without any adverse effects. A lower dose (100mg/kg/w) resulted in halted tumor growth, but no tumor regression (Supplemental The aim of this study was to investigate the potentially radiosensitizing effect of the NAMPT inhibitor GMX1778 on 177 Lu-DOTATATE treatment of NETs using a xenograft model.
MATERIALS AND METHODS

Animal model and xenografting
The xenograft model with human small intestinal NET cell line GOT1 in nude mice has been described previously (7). In brief, small pieces (about 1 mm) of excised tumor were transplanted subcutaneously to female BALB/c nude mice. All procedures were approved by the Ethical Committee for Animal Research at the University of Gothenburg.
Pharmaceuticals
GMX1778, (N-(6-chlorophenoxyhexyl)-N'-cyano-N"-4-pyridylguanidine) was formulated as a 20 mg/ml suspension in 2% carboxymethyl cellulose in 0.9% saline. The radiolabeling and quality control of with specific activity of 30 MBq/μg, was performed as previously described (2) .
Treatment with 177
Lu-DOTATATE and GMX1778
Animals were divided into 6 groups; controls (vehicle only, n=6), 177 Lu-DOTATATE (7.5 MBq, n=10), GMX1778x1 (single dose of 100 mg/kg, n=7), GMX1778x3 (3 weekly doses of 100 mg/kg, n=5), 177 Lu-DOTATATE (7.5 MBq) + GMX1778x1 (n=6) and 177 Lu-DOTATATE (7.5 MBq) + GMX1778x3 (n=5).
177
Lu-DOTATATE was injected in a tail vein and GMX1778 was given by oral gavage. In the combined therapy groups GMX1778 was given one hour after 177 Lu-DOTATATE.
Animals were followed up to 17 weeks and were killed when tumor weight exceeded 10% of body weight, or body weight was reduced by more than 10%. Animal weights and tumor sizes (longest diameter and the two perpendicular diameters measured by calipers) were monitored regularly. Tumor volumes were calculated by assuming spheroid tumor shapes (V = 4πr1r2r3/3). The relative tumor volume at a given time point was defined as the tumor volume divided by the volume at day 0.
Kidney uptake of 177
Lu-DOTATATE
Two groups of animals were given 177 Lu-DOTATATE (7.5 MBq, n=8) or 177 Lu-DOTATATE (7.5 MBq) + GMX1778x1 (single dose of 100 mg/kg, n=7), as described above.
After 24 hours animals were killed and the kidneys were weighed and 177 Lu activity measured using a gamma counter.
Quantitative Real-Time PCR (qPCR) of SSTR subtype 2 (SSTR2) mRNA GOT1 cells were cultured as previously described (3). Cells were then treated with GMX1778 at 10 nM, 20 nM or with vehicle control (0.2 % DMSO) for 1, 5 or 14 hours. For each condition and time point cells were seeded in duplicate and for each of these duplicates qPCR analysis was run in triplicate. The whole experiment was repeated three times. RNA extraction was performed using the RNeasy Micro Kit (Qiagen) according to the manufacturer's protocol. cDNA was synthesized using the High Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific). mRNA expression levels were analyzed using predesigned TaqMan Gene Expression Assay (Thermo Fisher Scientific): GAPDH (Hs99999905_m1), HPRT1 (Hs02800695_m1) and SSTR2 (Hs00990356_m1). The PCR reactions were performed using a 7500 Fast Real-Time PCR System (Applied Biosystems). For each RNA sample, the levels of SSTR2 mRNA expression are given relative to those of the two housekeeping genes GAPDH and HPRT1.
Immunohistochemical analysis of SSTR2 protein
GOT1 tumors were analyzed with respect to SSTR2 protein expression using immunohistochemistry. Sections from formalin-fixed, paraffin-embedded tumors were incubated with antibodies against SSTR2A (clone UMB1; Abcam, Cat no ab134152) followed by Dako EnVision™ FLEX+ system. Stained sections were evaluated with respect to staining intensity and the percentage of labeled tumor cells according to Körner et al. (8) .
In vitro measurement of NAD + GOT1 cells were cultured as previously described (3). Cells were divided into 4 groups; controls, GMX1778 (10nM), external radiation and GMX1778 (10nM) + external radiation.
Culture medium was changed, containing GMX1778 at 10 nM or 0 nM. After 1 hour incubation the culture plates were cooled on ice and irradiated at 1 Gy or 0 Gy, maintaining sterile conditions, and then further incubated at 37°C. 
Data analysis
Kaplan-Meier data for tumor volumes were analyzed using Cox regression followed by pairwise comparisons between groups using SAS (version 9.3, SAS Institute 
RESULTS
Treatment with GMX1778 increases the reduction of GOT1 tumor volume after 177
Lu-
DOTATATE
All 33 treated animals did well and only one animal in the control group had to be killed due to weight loss. The maximal tumor volume reduction after single semi-efficient doses of 177 Lu-DOTATATE (7.5 MBq) or GMX1778 (100 mg/kg) was seen after 2 weeks, when the average tumor volumes were reduced by 45% and 34%, respectively. Three weekly doses of GMX1778 resulted in a maximal tumor volume reduction of 53% at 3 weeks. Combining a single dose of 177 Lu-DOTATATE and a single dose of GMX1778 resulted in a more pronounced antitumor effect with a maximal reduction of 73% at 3 weeks. Combining (Fig. 2) .
GMX1778 treatment does not affect the uptake of 177
Lu-DOTATATE in kidneys
With clinical 177 Lu-DOTATATE treatment the kidneys are the main organs at risk and the kidney uptake is dose-limiting. GMX-treated animals had a mean uptake of 90 % of control animals, which was a non-significant difference according to Students t-test (data not shown).
GMX1778 treatment does not affect the expression of SSTR2 in GOT1 cells and GOT1 tumors
SSTR2 is often overexpressed in small intestinal NETs and is the most important receptor for 177
Lu-DOTATATE uptake and antitumor effect. A possible mechanism for the GMX1778 radiosensitizing effect could thus be upregulation of SSTR2. However, we found no alteration of SSTR2 gene expression in cultured GOT1 cells after GMX1778 treatment for 1, 5 or 14 hours (Supplemental Fig. 3A) . Furthermore, immunohistochemical analysis of GOT1 tumors did not reveal any differences in SSTR2 labeling intensity or the percentage of labeled tumors in GMX1778 treated animals compared with control animals (Supplemental Fig. 3B and 4) .
GMX1778 treatment reduces the amount of NAD + in GOT1 cells
Cultured GOT1 cells were incubated with GMX1778, 10 nM and/or irradiated with 1 Gy.
These doses of GMX1778 and external radiation have a small cytotoxic effect visible after several days, but no effect on cell viability within the first 24 hours (data not shown).
by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from GMX1778 had a clear NAD + -reducing effect already after 5 hours and a more pronounced effect after 14 hours (Fig. 3) . An alternative way to increase the antitumor effect of peptide-receptor radionuclide therapy might be the use of radiosensitizers, which act synergistically on DNA repair mechanisms to enhance tumor cell death (14) . One such mechanism is the radiation induced involving the rate-limiting enzyme NAMPT. GMX1778 inhibits NAMPT and can thereby, in the case of PARP-1 activation, reduce NAD + to lethally low levels (Fig. 4) (4) .
DISCUSSION
Following the identification of its mechanism of action -inhibition of NAD + synthesis via NAMPT inhibition -GMX1777/1778 has been shown to have a synergistic chemosensitizing effect, both in vitro and in vivo (16) . Radiosensitizing effects of NAMPT inhibitors FK866 and GMX1777 have also been demonstrated experimentally in breast cancer and head and neck cancer models, respectively (6,17).
In this study, we have confirmed previous findings that semi-efficient doses of 177 Lu-DOTATATE (7.5 MBq) or GMX1778 (100 mg/kg/w) results in temporary halted tumor growth or moderate regression in nude mice xenografted with the small intestinal NET GOT1. When these treatment modalities were combined, the same doses of Lu-DOTATATE and GMX1778 treatment remain to be elucidated. GMX1778 (CHS828) or its prodrug GMX1777 (teglarinad chloride or EB1627) have been evaluated as monotherapy in a few phase I/II studies on solid tumors, without any antitumor effects (18, 19) . GMX1778 plasma levels of about 10 M have been achieved in humans (19) , which is of the same order of magnitude as plasma levels with antitumor effects in mouse tumor models (20, 21) . The doses used in those animal experiments are about the same as the doses used in this work. 
